These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 33775724)

  • 1. Development of FDM 3D-printed tablets with rapid drug release, high drug-polymer miscibility and reduced printing temperature by applying the acid-base supersolubilization (ABS) principle.
    Patel NG; Serajuddin ATM
    Int J Pharm; 2021 May; 600():120524. PubMed ID: 33775724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving drug release rate, drug-polymer miscibility, printability and processability of FDM 3D-printed tablets by weak acid-base interaction.
    Patel NG; Serajuddin ATM
    Int J Pharm; 2023 Feb; 632():122542. PubMed ID: 36566823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Formulation of 3D Printed Tablet for Rapid Drug Release by Fused Deposition Modeling: Screening Polymers for Drug Release, Drug-Polymer Miscibility and Printability.
    Solanki NG; Tahsin M; Shah AV; Serajuddin ATM
    J Pharm Sci; 2018 Jan; 107(1):390-401. PubMed ID: 29066279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of 3D Printed Tablets by Fused Deposition Modeling Using Polyvinyl Alcohol as Polymeric Matrix for Rapid Drug Release.
    Wei C; Solanki NG; Vasoya JM; Shah AV; Serajuddin ATM
    J Pharm Sci; 2020 Apr; 109(4):1558-1572. PubMed ID: 32004538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An investigation into the use of polymer blends to improve the printability of and regulate drug release from pharmaceutical solid dispersions prepared via fused deposition modeling (FDM) 3D printing.
    Alhijjaj M; Belton P; Qi S
    Eur J Pharm Biopharm; 2016 Nov; 108():111-125. PubMed ID: 27594210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of release modifiers to modulate drug release from fused deposition modelling (FDM) 3D printed tablets.
    Shi K; Salvage JP; Maniruzzaman M; Nokhodchi A
    Int J Pharm; 2021 Mar; 597():120315. PubMed ID: 33540000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low temperature fused deposition modeling (FDM) 3D printing of thermolabile drugs.
    Kollamaram G; Croker DM; Walker GM; Goyanes A; Basit AW; Gaisford S
    Int J Pharm; 2018 Jul; 545(1-2):144-152. PubMed ID: 29705104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of immediate release (IR) 3D-printed oral dosage forms with focus on industrial relevance.
    Fanous M; Gold S; Hirsch S; Ogorka J; Imanidis G
    Eur J Pharm Sci; 2020 Dec; 155():105558. PubMed ID: 32946957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenges, current status and emerging strategies in the development of rapidly dissolving FDM 3D-printed tablets: An overview and commentary.
    Serajuddin ATM
    ADMET DMPK; 2023; 11(1):33-55. PubMed ID: 36778904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tailoring immediate release FDM 3D printed tablets using a quality by design (QbD) approach.
    Than YM; Titapiwatanakun V
    Int J Pharm; 2021 Apr; 599():120402. PubMed ID: 33640426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simplification of fused deposition modeling 3D-printing paradigm: Feasibility of 1-step direct powder printing for immediate release dosage form production.
    Fanous M; Gold S; Muller S; Hirsch S; Ogorka J; Imanidis G
    Int J Pharm; 2020 Mar; 578():119124. PubMed ID: 32035253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of Drug Load on the Printability and Solid-State Properties of 3D-Printed Naproxen-Based Amorphous Solid Dispersion.
    Kissi EO; Nilsson R; Nogueira LP; Larsson A; Tho I
    Molecules; 2021 Jul; 26(15):. PubMed ID: 34361646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3D printing of pharmaceutical oral solid dosage forms by fused deposition: The enhancement of printability using plasticised HPMCAS.
    Oladeji S; Mohylyuk V; Jones DS; Andrews GP
    Int J Pharm; 2022 Mar; 616():121553. PubMed ID: 35131354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can filaments be stored as a shelf-item for on-demand manufacturing of oral 3D printed tablets? An initial stability assessment.
    Okwuosa TC; Sadia M; Isreb A; Habashy R; Peak M; Alhnan MA
    Int J Pharm; 2021 May; 600():120442. PubMed ID: 33675925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Lower Temperature FDM 3D Printing for the Manufacture of Patient-Specific Immediate Release Tablets.
    Okwuosa TC; Stefaniak D; Arafat B; Isreb A; Wan KW; Alhnan MA
    Pharm Res; 2016 Nov; 33(11):2704-12. PubMed ID: 27506424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immediate Release 3D-Printed Tablets Produced Via Fused Deposition Modeling of a Thermo-Sensitive Drug.
    Kempin W; Domsta V; Grathoff G; Brecht I; Semmling B; Tillmann S; Weitschies W; Seidlitz A
    Pharm Res; 2018 Apr; 35(6):124. PubMed ID: 29679157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3D printing of immediate-release tablets containing olanzapine by filaments extrusion.
    Bhatt U; Malakar TK; Murty US; Banerjee S
    Drug Dev Ind Pharm; 2021 Aug; 47(8):1200-1208. PubMed ID: 33493008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Effective Technology for the Development of Immediate Release Solid Dosage Forms Containing Low-Dose Drug: Fused Deposition Modeling 3D Printing.
    Gültekin HE; Tort S; Acartürk F
    Pharm Res; 2019 Jun; 36(9):128. PubMed ID: 31250313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The applicability of pharmaceutical polymeric blends for the fused deposition modelling (FDM) 3D technique: Material considerations-printability-process modulation, with consecutive effects on in vitro release, stability and degradation.
    Ilyés K; Kovács NK; Balogh A; Borbás E; Farkas B; Casian T; Marosi G; Tomuță I; Nagy ZK
    Eur J Pharm Sci; 2019 Mar; 129():110-123. PubMed ID: 30610954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3D-Printed Isoniazid Tablets for the Treatment and Prevention of Tuberculosis-Personalized Dosing and Drug Release.
    Öblom H; Zhang J; Pimparade M; Speer I; Preis M; Repka M; Sandler N
    AAPS PharmSciTech; 2019 Jan; 20(2):52. PubMed ID: 30617660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.